Biological Safety Testing Market to Reach USD 16.25 Billion by 2033 at 12.6% CAGR; North America Leads with 39.5% Share - Key Players: Thermo Fisher Scientific, Merck KGaA, Charles River Laboratories

The global biological safety testing market was valued at USD 6.64 billion in 2025 and is projected to reach nearly USD 16.25 billion by 2033, growing at a CAGR of 12.6% during the forecast period from 2026 to 2033. The market is witnessing strong growth driven by the increasing production of biologics, vaccines, biosimilars, and cell and gene therapies across the pharmaceutical and biotechnology industries. Rising regulatory requirements for product quality and safety assurance, growing concerns regarding microbial contamination, and increasing demand for reliable sterility and toxicity testing solutions are significantly contributing to market expansion globally. Biological safety testing plays a crucial role in ensuring the purity, potency, and safety of biopharmaceutical products before commercialization, further supporting its widespread adoption across research laboratories and manufacturing facilities.

The market is also benefiting from continuous advancements in rapid microbiological testing methods, automated analytical platforms, molecular diagnostics technologies, and in vitro safety testing solutions that improve testing efficiency, accuracy, and turnaround time. Increasing investments in biopharmaceutical research and development, growing clinical trial activities, and expanding applications of biological safety testing in vaccine development, regenerative medicine, and personalized therapies are creating substantial growth opportunities across developed and emerging economies. Leading companies including Charles River Laboratories, Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, and WuXi AppTec are actively focusing on advanced testing technologies, strategic collaborations, and expansion of biologics testing capabilities to strengthen their presence in the global biological safety testing market.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/biological-safety-testing-market?sai-v

Key Developments

February 2026: Rising focus on biologics safety, vaccine quality assurance, and regulatory compliance accelerated growth in the Biological Safety Testing market across North America and Europe. Companies including Charles River Laboratories, Merck KGaA, and Thermo Fisher Scientific expanded biological safety testing and quality control service portfolios.

January 2026: Increasing adoption of cell-based assays, rapid microbial detection technologies, and AI-assisted laboratory analytics strengthened innovation in the market across the United States, Germany, Japan, and China. Biopharmaceutical companies increasingly utilized automated sterility testing and endotoxin detection platforms to improve manufacturing efficiency.

December 2025: Growing production of vaccines, monoclonal antibodies, and gene therapies accelerated demand for advanced biological safety testing solutions globally. Healthcare and biotechnology organizations expanded testing capabilities for adventitious agent detection, mycoplasma testing, and viral safety assessment.

November 2025: Expansion of regulatory frameworks and biologics manufacturing activities across Asia-Pacific and Europe strengthened deployment of biological safety testing technologies. Pharmaceutical manufacturers increasingly adopted advanced contamination detection and quality assurance systems for biologic products and biosimilars.

October 2025: Rising advancements in rapid sterility testing, PCR-based pathogen detection, and automated quality control technologies improved biological safety testing capabilities through continuous advancements globally. Research organizations focused on next-generation microbial detection systems and high-throughput analytical platforms.

September 2025: Increasing collaborations between pharmaceutical companies, CROs, and biotechnology firms accelerated development in biological safety testing solutions worldwide. Companies focused on AI-enabled laboratory workflows, real-time contamination monitoring, and digital quality management systems.

August 2025: Growing awareness regarding biologics safety, regulatory compliance, and contamination prevention strengthened expansion of the Biological Safety Testing market across Europe and Asia-Pacific. Biopharmaceutical manufacturers increasingly adopted advanced analytical testing services for vaccines, recombinant proteins, and cell therapies.

July 2025: Rising investments in biologics manufacturing infrastructure and laboratory automation accelerated progress in biological safety testing technologies globally. Companies including Lonza Group and WuXi AppTec expanded biologics testing and quality assurance capabilities.

June 2025: Increasing focus on biologics quality assurance, vaccine safety, and regulatory-driven pharmaceutical testing supported strong adoption in the global Biological Safety Testing market. North America remained the leading region, while Asia-Pacific emerged as the fastest growing market driven by expanding biopharmaceutical production, rising vaccine development activities, and increasing healthcare investments.

Key Players
Avance Biosciences | Cytovance Biologics | Eurofins Scientific | Lonza | Merck KGaA | Promega Corporation | Thermo Fisher Scientific | Toxikon | WuXi AppTec | Charles River Laboratories | Others

Key Highlights
Avance Biosciences - Holds a 14.8% share, driven by advanced biologics analytical testing capabilities, GMP-compliant bioassay expertise, and expanding biologic safety evaluation services.

Cytovance Biologics - Holds a 12.6% share, supported by biologics process development expertise, scalable GMP manufacturing infrastructure, and integrated safety testing capabilities.

Eurofins Scientific - Holds a 11.4% share, fueled by comprehensive pharmaceutical testing services, strong global laboratory network, and advanced microbiological safety assessment technologies.

Lonza - Holds a 10.1% share, driven by biologics quality assurance expertise, integrated cell and gene therapy testing solutions, and strong biopharmaceutical manufacturing support capabilities.

Merck KGaA - Holds a 8.9% share, strengthened by advanced biosafety testing reagents, analytical workflow integration technologies, and extensive life sciences product portfolios.

Promega Corporation - Holds a 7.3% share, supported by molecular testing technologies, innovative cell-based assay development, and strong biologics characterization expertise.

Thermo Fisher Scientific - Holds a 6.5% share, powered by broad laboratory instrumentation capabilities, biologics safety testing solutions, and strong global biopharma service infrastructure.

Toxikon - Holds a 5.2% share, driven by toxicology testing expertise, preclinical biosafety assessment services, and expanding pharmaceutical quality assurance capabilities.

WuXi AppTec - Holds a 4.6% share, strengthened by integrated CRO and CDMO services, biologics testing innovation, and large-scale pharmaceutical development support infrastructure.

Charles River Laboratories - Holds a 3.8% share, supported by preclinical research expertise, biologics safety evaluation services, and strong regulatory compliance testing capabilities.

Others - Hold a combined 15.0% share, comprising regional laboratory testing providers, contract research organizations, and emerging biologics safety assessment companies advancing next-generation biological safety testing technologies globally.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=biological-safety-testing-market?sai-v

Market Drivers

Increasing demand for biologics, vaccines, cell therapies, and gene therapies is significantly driving growth of the biological safety testing market worldwide.

Growing regulatory requirements for product safety, quality assurance, and contamination control in biopharmaceutical manufacturing are accelerating expansion of the biological safety testing market globally.

Rising prevalence of chronic diseases and increasing development of advanced biopharmaceutical products are strengthening demand for reliable biological safety testing solutions.

Increasing focus on sterility testing, endotoxin testing, bioburden testing, and viral safety evaluation is contributing to rapid commercialization of advanced biological safety testing technologies.

Continuous advancements in rapid microbiological methods, automation technologies, molecular diagnostics, and cell-based assays are improving testing accuracy, efficiency, and compliance outcomes.

Expansion of biopharmaceutical manufacturing facilities, contract research organizations, and vaccine production capabilities is improving adoption of biological safety testing services worldwide.

Growing investments from pharmaceutical companies, biotechnology firms, and healthcare organizations in quality control and biosafety infrastructure are accelerating innovation across the market.

Rising government regulations, international safety standards, and increasing focus on contamination-free biologic production are further propelling market growth globally.

Industry Developments

Rapid advancement in rapid microbial detection technologies and automated testing platforms improving efficiency and turnaround time in biological safety testing procedures.

Increasing adoption of molecular diagnostics, PCR-based testing methods, and next-generation sequencing supporting enhanced contamination detection and product safety assurance.

Growing investments in biologics manufacturing, vaccine development, and biosimilar production accelerating innovation in biological safety testing solutions.

Expansion of contract testing services and outsourced quality assurance operations improving accessibility and scalability of biological safety testing capabilities.

Rising collaborations among pharmaceutical companies, biotechnology firms, regulatory agencies, and contract research organizations driving development of advanced biosafety testing technologies.

Strategic product launches and commercialization of automated endotoxin testing systems, sterility testing platforms, and viral safety testing kits supporting global market expansion.

Continuous innovation in cell culture analysis, environmental monitoring systems, and AI-assisted laboratory automation improving testing precision and regulatory compliance.

Regional Insights

North America 39.5% share: "Leads the market due to advanced biopharmaceutical manufacturing infrastructure, strong regulatory compliance frameworks, high investments in biologics and vaccine development, and presence of leading biotechnology and pharmaceutical companies."

Europe 28.4% share: "Growth supported by stringent biosafety regulations, increasing biologics production, expanding vaccine research initiatives, and rising adoption of advanced quality assurance technologies."

Asia Pacific 24.7% share: "Fastest-growing region driven by expanding biopharmaceutical manufacturing capacity, increasing investments in biotechnology research, growing vaccine production activities, and improving healthcare infrastructure across China, India, Japan, and South Korea."

Latin America 4.0% share: "Emerging growth supported by improving pharmaceutical manufacturing standards, rising biologics adoption, and increasing investments in healthcare quality control infrastructure."

Middle East & Africa 3.4% share: "Gradual growth driven by expanding healthcare and pharmaceutical sectors, increasing awareness regarding biologic product safety, and rising adoption of advanced laboratory testing solutions."

Speak to our analyst and get customization in the report as per your requirements:https://www.datamintelligence.com/customize/biological-safety-testing-market?sai-v

Key Segments
➥ By Product

Reagents and Kits: Represents the dominant segment, driven by increasing demand for rapid biological safety testing procedures, routine quality control processes, and growing utilization in pharmaceutical and biotechnology industries.

Instruments: Represents a significant segment, supported by rising adoption of automated testing equipment, advanced analytical systems, and high-throughput biological safety testing technologies.

Other Products: Represents a moderate segment, fueled by growing demand for consumables, culture media, and specialized accessories used in biological safety testing workflows.

➥ By Application

Vaccines and Therapeutics: Represents the dominant segment, driven by increasing vaccine production activities, rising biologics development, and stringent regulatory requirements for product safety and quality assurance.

Cellular and Gene Therapy: Represents a rapidly growing segment, supported by expanding research in regenerative medicine, increasing commercialization of gene therapies, and rising demand for contamination-free biologic products.

Blood and Blood-based Therapy: Represents a significant segment, fueled by growing utilization of blood-derived products, plasma therapies, and strict safety testing requirements in transfusion medicine.

Other Applications: Represents a moderate segment, supported by increasing use of biological safety testing across research laboratories, medical device manufacturing, and biotechnology applications.

➥ By Test

Bioburden Tests: Represents a significant segment, driven by increasing need to detect microbial contamination during pharmaceutical and biologics manufacturing processes.

Sterility Tests: Represents the dominant segment, supported by stringent global regulatory standards requiring sterility assurance for injectable drugs, vaccines, and biologic products.

Endotoxin Tests: Represents a rapidly growing segment, fueled by rising demand for pyrogen detection in biologics, medical devices, and parenteral pharmaceutical products.

Other Tests: Represents a moderate segment, supported by expanding applications of mycoplasma testing, viral safety testing, and residual impurity analysis in advanced biologic manufacturing.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.